Akebia reports Q2 EPS (6c) vs. 15c last year

Reports Q2 revenue $56.4M vs. $126.4M last year. Cash and cash equivalents as of June 30, were approximately $53.6M. Akebia expects to fund its current operating plan with existing cash resources and cash from operations for at least the next twelve months. “Through 2023 we have worked to best position Akebia to deliver a new potential oral treatment option for anemia due to CKD to dialysis patients around the globe,” said John Butler, CEO. “This past quarter alone we made remarkable progress by gaining approval for vadadustat in 33 additional countries, securing Medice as our partner to bring Vafseo to patients in Europe in 2024 and clarifying the path to resubmission of the vadadustat NDA in the U.S. These impactful milestones mark significant progress toward our purpose to better the lives of people impacted by kidney disease.”